Kepler Cheuvreux starts Coloplast as “buy,” says de-rating overdone By Investing.com

Kepler Cheuvreux initiated Coloplast with a buy rating and a DKK482 target price versus a DKK404.40 share price, implying 19.2% upside. The broker said the recent de-rating has overshot fundamentals, citing the resilience of Coloplast’s core franchise, which represents about 85% of sales, while keeping 2026 and 2027 EPS estimates unchanged. The call supports a gradual re-rating thesis rather than relying on a sharp recovery at Kerecis.

Analysis

The key read-through is not the initiation itself, but the market’s willingness to separate a problem child from the core asset. If investors accept that the drag is isolated, this becomes a classic “good business, bad narrative” setup where valuation mean reversion can happen faster than fundamentals, especially in defensives with sticky demand and limited operating leverage on the downside. That tends to favor the highest-quality peers in the space as sentiment rotates toward businesses with similar recurring revenue profiles and less execution noise.

The second-order effect is that Kerecis is now acting like a litmus test for how much operational slippage the market will tolerate before discounting the entire platform. If the weakness persists, the risk is not just earnings dilution but multiple compression across the medtech group as investors demand a larger governance/execution discount for bolt-on acquisitions. Conversely, any stabilization there could trigger a sharper-than-expected rerating because positioning is likely still underweight after the de-rating phase.

The contrarian angle is that the crowd may be underestimating how rarely high-quality medtech franchises trade at trough multiples for long when core growth remains mid-single-digit and margins stay structurally high. The better setup is often to buy before the clean inflection in reported numbers, not after; if the market waits for evidence that Kerecis has normalized, most of the multiple recovery will already be gone. Time horizon matters here: this is a 3-12 month valuation repair trade, not a quick catalyst trade, unless management gives explicit evidence of core resilience in the next quarter.

For investors, the risk is that the market is correctly pricing in a longer integration/reset cycle than bulls want to admit, in which case the stock can stay cheap despite a sound core. But if consensus is too focused on the weaker unit, there is room for a 10-15% rerating just on narrative normalization alone, with incremental upside if estimates stop falling.

Key Decisions for Investors

• Go long Coloplast on weakness for a 3-6 month mean-reversion trade; target 12-15% upside if the market continues to discount the core franchise as a separate asset from Kerecis. Use a stop if the next update shows core growth slowing below mid-single digits.
• Pair trade: long Coloplast / short a lower-quality medtech peer with similar Europe exposure but weaker recurring demand, to isolate the rerating from franchise quality rather than sector beta. Best held into the next earnings print.
• If already long, sell downside puts 1-2 quarters out to monetize elevated skepticism; this expresses a bullish view while forcing entry at a lower effective basis if the market overreacts again.
• Avoid adding aggressively until there is evidence the market has stopped extrapolating Kerecis weakness across the group; the risk/reward improves materially only when the valuation discount remains while operational noise fades.